IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCR-ABL1 KINASE DOMAIN MUTATIONS

被引：0
|
作者：
Razga, F. [1 ]
Jurcek, T. [1 ]
Zackova, D. [1 ]
Dvorakova, D. [1 ,2 ]
Toskova, M. [1 ]
Jeziskova, I. [1 ]
Mayer, J. [1 ,2 ]
Racil, Z. [1 ,2 ]
机构：
[1] Univ Hosp Brno, Brno, Czech Republic
[2] Masaryk Univ Brno, CEITEC, Brno, Czech Republic
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1326
引用
收藏
页码：536 / 537
页数：2
相关论文
共 50 条
  • [31] BIOLOGICAL CHARACTERISTICS AND DYNAMICS OF BCR-ABL1 MULTIPLE MUTATIONS IN TYROSINE KINASE INHIBITOR RESISTANT CML
    Kim, S.
    Choi, S.
    Lee, S.
    Bang, J.
    Jeon, H.
    Oh, Y.
    Park, J.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 54 - 55
  • [32] BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons
    Skorski, Tomasz
    CHEMISTRY & BIOLOGY, 2011, 18 (11): : 1352 - 1353
  • [33] BCR-ABL1 Kinase Domain Mutation Analysis in an Irish Cohort of Chronic Myeloid Leukemia Patients
    McCarron, Sarah L.
    O'Connor, Lisa M.
    Langabeer, Stephen E.
    Conneally, Eibhlin
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2013, 17 (02) : 170 - 173
  • [34] Declaration of Bcr-Abl1 independence
    Zhao, Helong
    Deininger, Michael W.
    LEUKEMIA, 2020, 34 (11) : 2827 - 2836
  • [35] Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
    Singh Anand, Anand Prakash
    Umbarkar Prachi, Prachi
    Tousif, Sultan
    Lal, Hind
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 214 - 221
  • [36] Declaration of Bcr-Abl1 independence
    Helong Zhao
    Michael W. Deininger
    Leukemia, 2020, 34 : 2827 - 2836
  • [37] Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
    Braun, Thorsten
    Berrou, Jeannig
    Prudent, Renaud
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Adiceam, Emilie
    Paublant, Fabrice
    Baruchel, Andre
    Ghysdael, Jacques
    Gardin, Claude
    Dombret, Herve
    BLOOD, 2018, 132
  • [38] New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia
    Li, Zixuan
    Peng, Danyue
    Deng, Jun
    Xiong, Lv
    Yin, Ping
    Hu, Jing
    Qian, Chenjing
    Yao, Lan
    Yin, Hua
    Hong, Mei
    Wu, Qiuling
    CANCER MEDICINE, 2024, 13 (20):
  • [39] Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors
    Ma, W.
    Giles, F.
    Zhang, X.
    Wang, X.
    Zhang, Z.
    Lee, T. -S.
    Yeh, C. -H.
    Albitar, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2011, 33 (03) : 326 - 331
  • [40] BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
    Khorashad, Jamshid S.
    Kelley, Todd W.
    Szankasi, Philippe
    Mason, Clinton C.
    Soverini, Simona
    Adrian, Lauren T.
    Eide, Christopher A.
    Zabriskie, Matthew S.
    Lange, Thoralf
    Estrada, Johanna C.
    Pomicter, Anthony D.
    Eiring, Anna M.
    Kraft, Ira L.
    Anderson, David J.
    Gu, Zhimin
    Alikian, Mary
    Reid, Alistair G.
    Foroni, Letizia
    Marin, David
    Druker, Brian J.
    O'Hare, Thomas
    Deininger, Michael W.
    BLOOD, 2013, 121 (03) : 489 - 498
12345